A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
Pierre JohansenBarnaby HuntNeeraj N IyerTam Dang-TanRichard F PollockPublished in: Advances in therapy (2019)
Novo Nordisk A/S.